axlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusseaxlr_logo-2022_HD_bleudeprusse

  • SATT AxLR
    • SATT AxLR
    • Governance
    • Services for companies
    • Annual reports
  • Assisting you
    • Researchers
      • Call-for-projects
    • Companies
    • Startups
    • Practical guide
  • Technology offerings
    • Invest
      • In our technologies
      • In our startups
    • Technologies
    • Startups
    • AxLR TV
  • Working with AxLR
    • Purchasing & public procurement
    • Join us
    • Our startups are hiring
  • Media
    • News
    • Agenda
    • Press kit
    • Communication kit
  • Contact
English
  • French
✕
  • Home
  • News
  • Incorporation of the start-up NERVOSAVE THERAPEUTICS
Neocean remporte le Grand Prix Inn’Ovations
7 February 2021
AxLR will be a partner of the 10th Antibody Industrial Symposium
27 April 2022
24 January 2022
Categories
  • News
Tags

Incorporation of the start-up biotech company: NERVOSAVE THERAPEUTICS, dedicated to the development of therapeutic solutions for nerve diseases.

LOGO NERVOSAVE

Nicolas TRICAUD PhD, world renown scientist in the field of myelin and peripheral nerves, announces the incorporation of NERVOSAVE THERAPEUTICS (SAS) inMontpellier, France. NERVOSAVE THERAPEUTICS is a spinoff of INSERM supported by SATT AxLR, Region Occitanie and BIC Montpellier. NERVOSAVE THERAPEUTICS is building a technology platform to deliver advanced therapeutic products for peripheral nerve diseases. Its first product is a clinical phase entering gene therapy to treat patients suffering from Charcot-Marie-Tooth disease 1A (CMT 1A).
Additionally, NERVOSAVE THERAPEUTICS is generating a pipeline to treat other demyelinating CMT diseases, acquired demyelinating peripheral neuropathies such as diabetic peripheral neuropathy and Guillain-Barré syndrome and peripheral nerve tumours.

Verbatim : Nicolas Tricaud (acting CEO and CSO):
“NERVOSAVE THERAPEUTICS is the first biotech totally dedicated to solving the problem of peripheral nerve diseases. Our ambition is to leverage the promise of gene therapy and other advanced therapies to grow NERVOSAVE THERAPEUTICS as an international leader in the field of peripheral nerve diseases in the next 5 years. The millions patients suffering these dreadful and mostly unaddressed diseases deserve our best effort in this objective”.

WEBSITE
Share
0
Franck-Léopold Erstein
Franck-Léopold Erstein

Related posts

27 April 2022

AxLR will be a partner of the 10th Antibody Industrial Symposium


En savoir +
7 February 2021

Neocean remporte le Grand Prix Inn’Ovations


En savoir +
15 January 2021

Perpignan at CES 2021


En savoir +

Comments are closed.

© 2023, AxLR - SATT Occitanie Méditerranée. All rights reserved. | Legal terms & Privacy policy
English
  • English
  • French